Michael Mullette Joins MAPS PBC Senior Leadership as Chief Operating Officer
March 29, 2022
On March 8, MAPS Public Benefit Corporation (MAPS PBC) announced that Michael Mullette, an experienced drug development and commercialization expert, has joined its senior leadership team as Chief Operating Officer. Mullette most recently served as the Vice President and Managing Director of North America for Moderna, where he oversaw commercialization of the company’s COVID-19 vaccine during the height of the pandemic.
Mullette joins MAPS PBC after more than 20 years in the pharmaceutical industry. Prior to his work at Moderna, Mullette developed broad pharmaceutical expertise with Sanofi in a variety of management roles in the U.S., Australia, France, Japan, and Canada. He holds a B.S. in Marketing from Villanova University, and an M.B.A. from Lehigh University. We are thrilled to have Michael’s expertise guiding the development of MDMA-assisted therapy for PTSD! Read our full statement here.
Results for Phase 1 Randomized Controlled Trial of MDMA and Fear Extinction Retention in Healthy Adults Published in Psychopharmacology
On February 15, 2022, the results of the MAPS-sponsored study by Barbara Rothbaum and team evaluating MDMA on the startle response in healthy adults was published in the medical journal Psychopharmacology. This randomized, blinded, placebo-controlled Phase 1 mechanism of action study investigated the effects of MDMA on startle testing learning in healthy volunteers in comparison to a placebo control. Visit the study’s webpage to learn more and view a timeline of the study’s history.
Journal of Psychiatric Research Publishes Results of Eating Behavior from Multi-Site Phase 3 Study of MDMA-Assisted Therapy for PTSD (MAPP1)
An analysis of eating behavior in study participants undergoing treatment in our Phase 3 study of MDMA-assisted therapy for PTSD was published in the Journal of Psychiatric Research on March 10, 2022. Eating disorders are common in individuals with PTSD, and MDMA-assisted therapy significantly reduced eating disorder symptoms compared to therapy with a placebo among participants with severe PTSD.
Refer Talent to MAPS to Win Prizes
You could win prizes for referring a friend to MAPS, MAPS Public Benefit Corporation (MAPS PBC), and MAPS Europe for one of over 30 open job opportunities! For each candidate you refer before April 1, you’ll be entered into a drawing to win prizes including a MAPS swag pack and an invitation to a virtual Meet & Greet with Rick Doblin, Ph.D., Founder and Executive Director of MAPS, or Amy Emerson, CEO of MAPS PBC. Do you know the perfect new Major Gifts Officer, Medical Monitor, or Head of Medical Science and Safety? Let them know about opportunities at MAPS.
Donate to MAPS to Win a Trip to Lightning in a Bottle Festival
When you make a donation to MAPS using this link, you’ll be entered to win a trip for you and a friend to Lightning in a Bottle Festival! Fly to Southern California to see musical acts including Glass Animals, KAYTRANADA, GRiZ, Big Wild, CloZee, Black Coffee, Four Tet, and many more! Support MAPS and help us continue our mission of healing for all.
Subscribe to the Psychedelic Science 2023 Email List
Mark your calendar for Psychedelic Science 2023, taking place from June 17-25, 2023! MAPS members, researchers, students, clinicians, therapists, political leaders, and psychedelic enthusiasts will gather from around the world to share the latest advances in psychedelic research. Be sure to sign up for exclusive email updates to receive news, schedules, and details about this extraordinary event.
Follow MAPS on Facebook, Twitter, Instagram, YouTube, and LinkedIn.
From all of us here at MAPS, we hope you are well and safe. Thank you for subscribing to the monthly MAPS Newsletter!
With appreciation,
MAPS
Treating PTSD with MDMA-Assisted Therapy
Results for Phase 1 Randomized Controlled Trial of MDMA and Fear Extinction Retention in Healthy Adults Published in Psychopharmacology
Enrollment Continues in Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Therapy with an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects with PTSD in Europe
MDMA Therapy Training Program Update: March 2022
FDA Places Open-Label Feasibility and Safety Study of MDMA-Assisted Group Therapy for the Treatment of Posttraumatic Stress Disorder in Veterans (MPG1) On Clinical Hold
Investigator-Initiated Trials Update
Expanded Access Study Site in California Begins Screening
Support MAPS
February Giving Report: Donors Give Over $1.1 Million to Psychedelic Research and Education
Psychedelic Peer Support
Zendo Project to Attend Burning Man, Lightning In A Bottle Update
MAPS in the Media
- The New York Times: Dr. Bronner’s, the Soap Company, Dips Into Psychedelics
- Business Insider: 5 People Who Used Psychedelics to Treat PTSD Describe Their Experiences
- NextAvenue: It May Be Time to Change Your Mind About Psychedelics
- The Harvard Crimson: At Harvard, Psychedelic Drugs’ Tentative Renaissance
- Forbes: Exclusive: MAPS Accepts $500,000 Donation From Atai Life Sciences’ Philanthropy Arm
- Business Insider: Meet the 16 Most Influential Women Shaping the Future of Psychedelics
- World Journal: American Phenomenon / From Psychedelics to Awakeners: Unorthodox Psychotherapy (Article in Chinese)
